[Chronic osteomyelitis due to Pseudomonas aeruginosa: treatment with elastomeric infusor in an outpatient setting].
Chronic bacterial osteomyelitis requires long-term antibiotic treatment (at least 6-8 weeks). After in-hospital management, patients are usually discharged and treated in outpatient settings. However, when the aetiology is represented by Gram-negative microorganisms, outpatient treatment could be difficult. Beta-lactam administration by means of an elastomeric infusor may represent an attractive approach. We report two cases of osteomyelitis due to Pseudomonas aeruginosa successfully treated with continuous ceftazidime administration via an elastomeric infusor in outpatient settings. In both cases the patients were free from clinical and laboratory signs of osteomyelitis at the end of treatment and after 12 months follow-up.
S.C. Malattie Infettive e Ortopedia Settica, Italy.
G
G
Carrega
V
V
Bartolacci
G
G
Burastero
G
G
Casalino Finocchio
M
M
Izzo
A
A
Ronca
L
L
Santoriello
S
S
Tigano
G
G
Riccio
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002442:Ceftazidime / Q000627:therapeutic use*; D002908:Chronic Disease; D048909:Diabetes Complications / Q000188:drug therapy / Q000382:microbiology; D020724:Elastomers; D004867:Equipment Design; D005500:Follow-Up Studies; D006801:Humans; D007260:Infusion Pumps; D007263:Infusions, Parenteral / Q000379:methods; D008297:Male; D008875:Middle Aged; D010019:Osteomyelitis / Q000188:drug therapy / Q000382:microbiology*; D010045:Outpatients; D011552:Pseudomonas Infections / Q000150:complications* / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012307:Risk Factors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D020724:Elastomers; D002442:Ceftazidime